Read More Pharma Industry News Novo Nordisk’s $2.1bn Corvidia bet faces impairment after ZEUS trial miss Ziltivekimab’s Phase 3 failure sends Novo Nordisk down 9%, triggers a Corvidia impairment and weakens its cardiovascular expansion strategy. bySoujanya RaviAugust 2, 2026